Press Release Archives - VICO Therapeutics

US FDA grants VICO Therapeutics Orphan-Drug Designation for VO659, an Investigational Therapy for Huntington Disease

by VICO Therapeutics | Jul 29, 2021 | Press Release

Leiden, The Netherlands, 29 July 2021 – VICO Therapeutics,a Leiden Bio Science Park, the Netherlands, based biotech company focusing on the development of RNA modulating therapies for rare neurological disorders, today announced that the Office of Orphan...

US FDA grants VICO Therapeutics Orphan-Drug Designation for VO659, an Investigational Therapy for Spinocerebellar Ataxia

by VICO Therapeutics | Jun 29, 2021 | Press Release

Leiden, The Netherlands, 29 June 2021 – VICO Therapeutics,a Leiden, the Netherlands, based biotech company focusing on the development of RNA modulating therapies for rare neurological disorders, today announced that the Office of Orphan Products...

European Commission grants VICO Therapeutics Orphan Drug Designation for VO659, an Investigational Therapy for Spinocerebellar Ataxia

by VICO Therapeutics | Feb 10, 2021 | Press Release

Leiden, The Netherlands, 10 February 2021 – VICO Therapeutics, a Leiden, the Netherlands, based biotech company focusing on the development of RNA modulating therapies for rare neurological disorders, today announced that the European Commission (EC) has granted...

Dutch VICO Therapeutics strengthens leadership team with the appointment of Rupert Sandbrink as Chief Medical Officer and Anders Hinsby as Independent Director

by VICO Therapeutics | Oct 1, 2020 | Press Release

Sandbrink, M.D., Ph.D. is a highly accomplished pharmaceutical executive with many years of clinical development, medical affairs, and regulatory experience at Topas, Bayer and Schering. Hinsby, Ph.D. is a seasoned life science entrepreneur and a co-founder and former...

Biotech VICO Therapeutics raises $31 million (€27 million) in Series A financing round to advance therapies for rare central nervous system diseases

by VICO Therapeutics | Jul 29, 2020 | Press Release

AON-platform with focus on therapies nearing phase I trials for forms of Spinocerebellar Ataxia and Huntington Disease Other early discovery stage RNA editing platform focuses on RETT syndrome Funding led by LSP, co-led by Kurma Partners, supported by Pontifax, Droia...